Consensus ACADIA Pharmaceuticals Inc.

Stocks

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
24.84 ^USD	+0.04%		-2.97%	-7.00%

07-20	Acadia Pharmaceuticals Inc. Receives FDA Fast Track Designation for Remlifanserin in Alzheimer?S Disease Psychosis	CI
07-20	Acadia Pharmaceuticals Receives US FDA Fast Track Designation for Alzheimer's Disease Psychosis Treatment	MT

Evolution of the Average Target: ACADIA Pharmaceuticals Inc.

Evolution of the Target Price: ACADIA Pharmaceuticals Inc.

Changes in Analyst Recommendations: ACADIA Pharmaceuticals Inc.

66df9ab3f9ad96.Te6FiMu-aU5B2POyVTsKx9iJkYGlL97o3eTQ3_KguLU.dbTKwqOOO3Y2lZfGDQ1_le7qwbTsWJuglbSFq5aVwuEbj-b7-_ozNhiUhA~3d4fc695f1e911df7adba7231215541d

Analysts' recommendations: ACADIA Pharmaceuticals Inc.

07-07	RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $29, Maintains Outperform Rating	MT
06-29	Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating	MT
04-07	RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating	MT
03-25	ACADIA Pharmaceuticals Shares Rise After BofA Upgrade	MT
03-25	BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29	MT
03-24	Acadia Pharmaceuticals' Remlifanserin Shows Favorable Setup Ahead of Phase 2 Data, RBC Says	MT
02-26	RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $31, Keeps Outperform Rating	MT
02-26	Morgan Stanley Lifts Price Target on ACADIA Pharmaceuticals to $26 From $25, Keeps Equalweight Rating	MT
02-23	Acadia Pharmaceuticals Shares Rise After Mizuho Upgrade	MT
02-23	Mizuho Upgrades ACADIA Pharmaceuticals to Outperform From Neutral, Adjusts Price Target to $35 From $29	MT
02-03	Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says	MT
02-03	RBC Cuts Price Target on ACADIA Pharmaceuticals to $31 From $35, Keeps Outperform Rating	MT
02-03	Deutsche Bank Trims Price Target on ACADIA Pharmaceuticals to $32 From $33, Keeps Buy Rating	MT
01-20	RBC Raises Price Target on ACADIA Pharmaceuticals to $35 From $33, Keeps Outperform Rating	MT
01-08	RBC Lifts Price Target on ACADIA Pharmaceuticals to $33 From $32, Keeps Outperform Rating	MT
01-06	UBS Adjusts Price Target on ACADIA Pharmaceuticals to $40 From $35, Maintains Buy Rating	MT
12-04	UBS Adjusts ACADIA Pharmaceuticals Price Target to $35 From $39, Maintains Buy Rating	MT
11-06	RBC Cuts Price Target on ACADIA Pharmaceuticals to $32 From $34, Keeps Outperform Rating	MT
25-10-08	RBC Cuts Price Target on ACADIA Pharmaceuticals to $34 From $40, Keeps Outperform Rating	MT
25-10-02	Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®?	CI
25-09-25	Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says	MT
25-09-25	Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating	MT
25-09-09	UBS Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $36, Maintains Buy Rating	MT
25-08-08	UBS Adjusts Price Target on ACADIA Pharmaceuticals to $36 From $32, Maintains Buy Rating	MT
25-08-07	RBC Lifts Price Target on ACADIA Pharmaceuticals to $40 From $39, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ACADIA PHARMACEUTICALS INC.					+32.05%
	LONZA GROUP AG					+23.65%
	REVOLUTION MEDICINES, INC.					+9.39%
	BEONE MEDICINES AG					+27.54%
	IQVIA HOLDINGS INC.					+11.51%
	CELLTRION, INC.					+44.52%
	MEDPACE HOLDINGS, INC.					-5.11%
	ASCENDIS PHARMA A/S					+19.91%
	EUROFINS SCIENTIFIC SE					+8.58%
	ICON PUBLIC LIMITED COMPANY					+9.68%
	Average					+18.17%
	Weighted average by Cap.					+19.01%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.84USD

Average target price

32.80USD

Spread / Average Target

+32.05%

High Price Target

45.00USD

Spread / Highest target

+81.16%

Low Price Target

17.00USD

Spread / Lowest Target

-31.56%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Deutsche Bank Securities
BofA Securities
Morgan Stanley
Mizuho Securities
UBS
Oppenheimer
Guggenheim
Stifel Nicolaus
JPMorgan Chase
Cantor Fitzgerald
Baird
Needham & Co.
Canaccord Genuity
JMP Securities
Citigroup
HC Wainwright
Goldman Sachs
Loop Capital
SVB Securities LLC
Cowen
Jefferies & Co.
Berenberg Bank
SMBC Nikko
SVB Leerink
Raymond James